Claudia A McCarthy, Robert E Widdop, Kate M Denton, Emma S Jones
Index: Curr. Hypertens. Rep. 15(1) , 25-30, (2013)
Full Text: HTML
It is quite well established that activation of the AT(2) receptor (AT(2)R) provides a counter-regulatory role to AT(1)R overactivity, particularly during pathological conditions. Indeed, a potential therapeutic role for the AT(2)R is currently being promulgated with the introduction of novel AT(2)R ligands such as compound 21 (C21). In this brief review, we will focus on recent evidence to suggest that AT(2)R exhibits promising organ protection in the context of the heart, kidney and brain, with inflammation and gender influencing outcome. However, this field is not without controversy since the 'flagship' ligand C21 has also come under scrutiny, although it is safe to say there is much evidence to support a potentially important role of AT(2)R in a number of cardiovascular diseases. This report updates recent data in this field.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Angiotensin II Receptor Ligand
CAS:127060-75-7 |
C52H69N13O11 |
|
Altered efficacy of AT1R-targeted treatment after spontaneou...
2011-01-01 [BMC Cancer 11 , 274, (2011)] |
|
Angiotensin III modulates the nociceptive control mediated b...
2009-12-15 [Neuroscience 164(3) , 1263-73, (2009)] |
|
Increased vascular angiotensin type 2 receptor expression an...
2009-03-01 [Am. J. Physiol. Heart Circ. Physiol. 296(3) , H745-55, (2009)] |
|
Angiotensin II type 2 receptor vasoactivity in internal mamm...
2007-10-01 [J. Cardiovasc. Pharmacol. 50(4) , 372-9, (2007)] |
|
Angiotensin II AT(2) receptor decreases AT(1) receptor expre...
2012-06-01 [J. Hypertens. 30(6) , 1176-84, (2012)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
